Tempest Therapeutics, Inc. (TPST)
| Market Cap | 93.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.18M |
| Shares Out | 925,432 |
| EPS (ttm) | -20.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,324 |
| Open | 13.72 |
| Previous Close | 13.90 |
| Day's Range | 13.50 - 14.10 |
| 52-Week Range | 10.39 - 41.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 9, 2021 |
About TPST
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is hea...
Financial Performance
Financial StatementsNews
Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin...
Tempest to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combi...
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
Closed merger transaction resulting in public listing (TPST)
H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest Therapeutics
H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and $51 price target, seeing an upside potential of over 100%. A strategic portfolio of targeted ther...
What's Going On With Tempest Therapeutics Stock?
Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. (NASDAQ: TPST) were soaring Monday for a second consecutive trading session on above-average volume. Tempest's Wild ...
TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-Merger
Tempest Therapeutics (TPST) stock is rocketing higher on Monday and reaching new highs since its merger with Millendo Therapeutics. The post TPST Stock: 13 Things to Know About Tempest Therapeutics as S...
Tempest to Participate in William Blair 2021 Biotech Focus Conference
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin...
Tempest Announces Appointment of Christine Pellizzari to its Board of Directors
SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that co...
Tempest Closes Merger with Millendo and Completes PIPE Financing
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics...
Tempest and Millendo Announce Stockholder Approval of Merger
Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”
SHAREHOLDER ALERT: WeissLaw LLP Investigates Millendo Therapeutics, Inc.
NEW YORK, April 27, 2021 /PRNewswire/ -- If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: ht...
MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Mi...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therape...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
NEW YORK, April 2, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...
Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeut...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair t...
Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics mo...
Tempest and Millendo Announce Proposed Merger Agreement
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics and Tempest Therapeutics announce a proposed merger agreement.
Millendo Therapeutics Provides Pipeline and Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.
Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.
3 Net Net Working Capital Stocks to Have a Look At
There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reassessed the s...
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with sig...
Millendo Therapeutics to Participate in September Investor Conferences
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Is the Options Market Predicting a Spike in Millendo (MLND) Stock?
Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.
Will Millendo Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.